SCHEMBL1099375

SCHEMBL1099375

O=S(=O)(Nc1cc[c]cc1)C1CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.47
SGK1 O00141 2/20 0.41
BRPF1 P55201 2/20 0.41
MAP2K4 P45985 2/20 0.40
UCHL1 P09936 1/20 0.39
USP30 Q70CQ3 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
OPRM1 P35372 1/20 0.37
KIT P10721 1/20 0.36
BRD4 O60885 2/20 0.35
EPHX2 P34913 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MAP2K7 O14733 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1267272 0.92 SGK1 (0.43) HDAC4SGK1BRPF1MAP2K4UCHL1
SCHEMBL6850398 0.79 HDAC4 (0.56) HDAC4SGK1BRPF1MAP2K4UCHL1
SCHEMBL4573296 0.78 HDAC4 (0.43) HDAC4SGK1BRPF1MAP2K4UCHL1
SCHEMBL31678785 0.76 PTGS1 (0.53) HDAC4SGK1BRPF1MAP2K4PTGS1
SCHEMBL21590270 0.76 CA1 (0.53) HDAC4SGK1BRPF1MAP2K4HRH3
SCHEMBL14830078 0.76 MAP2K4 (0.56) HDAC4SGK1BRPF1MAP2K4KIT
SCHEMBL3088517 0.76 SGK1 (0.51) HDAC4SGK1BRPF1MAP2K4HRH3
SCHEMBL3980159 0.76 CA1 (0.53) HDAC4SGK1BRPF1MAP2K4HRH3
SCHEMBL28207342 0.76 HDAC4 (0.47) HDAC4SGK1BRPF1MAP2K4UCHL1
SCHEMBL257524 0.76 CA1 (0.53) HDAC4SGK1BRPF1MAP2K4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9765054-B2 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2017-09-19 US claimed
US-20140163009-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation (US) 2014-06-12 US claimed
EP-2667709-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation, Inc. (US) 2013-12-04 EP claimed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP claimed
WO-2012103008-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. (US) 2012-08-02 WO claimed
EP-2183239-A1 SULFONAMIDES AS TRPM8 MODULATORS Janssen Pharmaceutica, N.V. (BE) 2010-05-12 EP claimed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US claimed
WO-2009012430-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-22 WO claimed
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 US claimed
EP-1798229-A1 SUBSTITUTED BIPHENYL DERIVATIVE Sankyo Company, Limited (JP) 2007-06-20 EP claimed
US-12024511-B2 Substituted imidazo[1,2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO., LTD. (CN) 2024-07-02 US disclosed
US-20200361934-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF JN THERAPEUTICS LTD. (CN) 2020-11-19 US disclosed
EP-3250572-B1 SUBSTITUTED IMIDAZO [1, 2-A]PYRIDIN-2-YLAMINE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF SHANGHAI FUDAN ZHANGJIANG BIO PHARMACEUTICAL CO LTD (CN) 2020-08-26 EP disclosed
US-10730875-B2 Substituted imidazo[1,2-A]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof JN THERAPEUTICS (CN) 2020-08-04 US disclosed
CN-107428749-B Substituted imidazo [1,2- α ] pyridin-2-ylamine compounds, pharmaceutical compositions and methods of use thereof 上海复旦张江生物医药股份有限公司 2020-07-24 CN disclosed
EP-2183239-A1 SULFONAMIDES AS TRPM8 MODULATORS Janssen Pharmaceutica, N.V. (BE) 2010-05-12 EP disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed
WO-2009012430-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-22 WO disclosed
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 US disclosed
EP-1798229-A1 SUBSTITUTED BIPHENYL DERIVATIVE Sankyo Company, Limited (JP) 2007-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163009-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF HDAC1, HDAC7, HDAC5 HDAC4 10/4885SGK1 1506/4885BRPF1 1215/4885
US-12024511-B2 Substituted imidazo[1,2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof JAK1, JAK2, JAK3 HDAC4 1392/4885SGK1 94/4885BRPF1 2868/4885
US-10730875-B2 Substituted imidazo[1,2-A]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof JAK1, JAK2, JAK3 HDAC4 1392/4885SGK1 94/4885BRPF1 2868/4885
US-20070275968-A1 Substituted Biphenyl Derivative COL2A1, COL1A1, FGFR3 HDAC4 441/4885SGK1 4284/4885BRPF1 445/4885
US-20200361934-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF JAK1, JAK2, JAK3 HDAC4 1392/4885SGK1 94/4885BRPF1 2868/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 HDAC4 1280/4885SGK1 1722/4885BRPF1 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.